M. Castro, L. Araujo, and W. C. Nahas, Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies, Transplant Proc, vol.36, pp.874-880, 2004.

D. C. Brennan, J. A. Daller, K. D. Lake, D. Cibrik, D. Castillo et al., Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation, N Engl J Med, vol.355, pp.1967-77, 2006.

S. Yang, D. Wang, and W. Wu, Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen, Transpl Immunol, vol.18, pp.281-286, 2008.

M. M. Brokhof, H. W. Sollinger, and D. R. Hager, Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients, Transplantation, vol.97, pp.612-619, 2014.

J. Pascual, S. P. Berger, and O. Witzke, Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, J Am Soc Nephrol, vol.29, pp.1979-91, 2018.

L. Oostenbrink, C. M. Jol-van-der-zijde, and K. Kielsen, Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation, Front Immunol, vol.10, p.315, 2019.

I. Popow, J. Leitner, and K. Grabmeier-pfistershammer, A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations, Am J Transplant, vol.13, pp.3103-3116, 2013.

F. Burkhalter, S. Schaub, and C. Bucher, A Comparison of Two Types of Rabbit Antithymocyte Globulin Induction Therapy in Immunological High-Risk Kidney Recipients: A Prospective Randomized Control Study, PLoS ONE, vol.11, p.165233, 2016.

L. Rostaing, L. Lavayssière, and N. Kamar, Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients, Exp Clin Transplant, vol.8, pp.178-80, 2010.

H. Ekberg, H. Tedesco-silva, and A. Demirbas, Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, New England Journal of Medicine, vol.357, pp.2562-75, 2007.

M. D. Stegall, L. D. Cornell, W. D. Park, B. H. Smith, and F. G. Cosio,

, Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury, Am J Transplant, vol.18, pp.180-188, 2018.

J. R. Chapman, Chronic calcineurin inhibitor nephrotoxicity-lest we forget, Am J Transplant, vol.11, pp.693-700, 2011.

R. M. Langer, R. Hené, and S. Vitko, Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation, Transpl Int, vol.25, pp.592-602, 2012.

C. Sommerer, B. Suwelack, and D. Dragun, An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients, Kidney Int, vol.96, pp.231-275, 2019.

S. Davis, J. Gralla, and P. Klem, Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation, Am J Transplant, vol.18, pp.907-922, 2018.

H. Tedesco-silva, J. Pascual, and O. Viklicky, Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study, Transplantation, vol.103, pp.1953-63, 2019.

M. Haas, B. Sis, and L. C. Racusen, Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions, Am J Transplant, vol.14, pp.272-83, 2014.

A. Loupy, M. Haas, and K. Solez, Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology, Am J Transplant, vol.17, pp.28-41, 2015.

. R-core-team, , 2019.

, European Environment Agency

A. Gafter-gvili and U. Gafter, Posttransplantation Anemia in Kidney Transplant Recipients

, Acta Haematol, vol.142, pp.37-43, 2019.

H. Jones, M. Talwar, and J. M. Nogueira, Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a timevarying analysis, Transplantation, vol.93, pp.923-931, 2012.

A. Schechter, A. Gafter-gvili, and D. Shepshelovich, Post renal transplant anemia: severity, causes and their association with graft and patient survival, BMC Nephrol, vol.20, p.51, 2019.

B. Schnetzler, P. Leger, and A. Völp, A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in firstheart transplant recipients, Transpl Int, vol.15, pp.317-342, 2002.

A. Gharekhani, T. Entezari-maleki, S. Dashti-khavidaki, and H. Khalili, A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation, Expert Opin Biol Ther, vol.13, pp.1299-313, 2013.

S. Sofroniadou, D. Goldsmith, A. Cumpelik, E. Gerossier, and J. Jin, Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects, Am J Transplant, vol.34, pp.2588-601, 2011.

C. Chen, A. Koenig, and C. Saison, CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression, Front Immunol, vol.9, p.275, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02003936

J. Bamoulid, T. Crepin, and E. Gaiffe, Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins, Transpl Immunol, vol.45, pp.48-52, 2017.

H. Issa, N. Sharma, and Q. Zhao, Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant, vol.25, pp.1993-2001, 2019.

M. I. De-paula, S. Bae, and A. A. Shaffer, The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-Risk Kidney Transplant Recipients without Pharmacological Prophylaxis, Transplantation, 2020.

C. Wu, I. Evans, and R. Joseph, Comorbid conditions in kidney transplantation: association with graft and patient survival, J Am Soc Nephrol, vol.16, pp.3437-3481, 2005.

J. Pratschke, D. Dragun, and I. A. Hauser, Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation, Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, vol.30, pp.77-84, 2016.

, KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant, vol.9, issue.3, pp.1-155, 2009.

T. Silva, H. Cibrik, D. Johnston, and T. , Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients, Am J Transplant, vol.10, pp.1401-1414, 2010.

, Il faut noter que les autres facteurs de risque hémorragique de nos receveurs tels que la prise de traitement anticoagulant ou les anomalies de la coagulation n'ont pas été relevés dans cette étude, ce qui a pu masquer une éventuelle différence. Dans cette période critique à haut risque hémorragique qu'est la première semaine après transplantation, lié aux perturbations de l'hémostase induites par l'insuffisance rénale terminale et la chirurgie

, La principale est l'extrême variabilité des patients inclus, liée au caractère rétrospectif de l'étude. Par exemple, les patients recevant un schéma GRA-EVR étaient significativement plus jeunes, Notre étude possède des limites évidentes

, En conclusion, l'association GRA plus EVR semble être pourvoyeuse d'un sur-risque de thrombopénie qu'il ne faut pas négliger, bien que n'ayant montré aucune conséquence en pratique clinique. Peu étudiée dans la littérature, cette association présente des résultats rassurants quant à ses répercussions sur la